Covered recipient · General Payments record
LIUDMYLA OLEKSIYIVNA INGLE
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$2,169.64
- Reported across 45 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $647.16 | 13 |
| Education | $258.97 | 3 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $162.81 | 5 |
| Apellis Pharmaceuticals, Inc. | $124.69 | 1 |
| E.R. Squibb & Sons, L.L.C. | $122.10 | 1 |
| Janssen Biotech, Inc. | $99.99 | 1 |
| Acerta Pharma LLC | $91.82 | 1 |
| PFIZER INC. | $89.00 | 2 |
| SANOFI-AVENTIS U.S. LLC | $83.99 | 1 |
| Tempus AI, Inc | $74.83 | 1 |
| Celgene Corporation | $42.43 | 2 |
| SOBI, INC | $14.47 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | $124.69 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154032197 | CMS |
| AstraZeneca Pharmaceuticals LP | $91.82 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104453030 | CMS |
| Celgene Corporation | $19.95 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101090683 | CMS |
| Celgene Corporation | $22.48 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101090687 | CMS |
| E.R. Squibb & Sons, L.L.C. | $122.10 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101252828 | CMS |
| Gilead Sciences, Inc. | $124.99 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133693488 | CMS |
| Gilead Sciences, Inc. | $10.08 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133693490 | CMS |
| Gilead Sciences, Inc. | $5.29 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133693492 | CMS |
| Gilead Sciences, Inc. | $12.99 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133693494 | CMS |
| Gilead Sciences, Inc. | $9.46 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133693496 | CMS |
| Janssen Biotech, Inc. | $99.99 | 07/01/2024 | Education | Undisputed | 01/23/2026 | 1078756576 | CMS |
| PFIZER INC. | $74.99 | 05/22/2024 | Education | Undisputed | 01/23/2026 | 1131484309 | CMS |
| PFIZER INC. | $14.01 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131313926 | CMS |
| SANOFI-AVENTIS U.S. LLC | $83.99 | 05/20/2024 | Education | Undisputed | 01/23/2026 | 1139920458 | CMS |
| SOBI, INC | $14.47 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141425205 | CMS |
| Tempus AI, Inc | $74.83 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150182650 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.